Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance

Haemophilia

Volumn 18, Issue 1, 2012, Pages 108-111

  Mangiafico, L ^a   Perja, M ^a   Fusco, F ^a   Riva, S ^a   Mago, D ^a   Gringeri, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Effectiveness; HAART; Haemophilia; HIV; Raltegravir; Safety

Indexed keywords

ATAZANAVIR; BLOOD CLOTTING FACTOR; DARUNAVIR; ETRAVIRINE; LAMIVUDINE; MARAVIROC; RALTEGRAVIR; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; BLEEDING; BLOOD ANALYSIS; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CHILD; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; FEMALE; HEMOPHILIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; MULTIDRUG RESISTANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RNA VIRUS; SCHOOL CHILD; SUBSTITUTION THERAPY; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE, VIRAL; HEMOPHILIA A; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; ITALY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PYRROLIDINONES; RETROSPECTIVE STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 84355162246     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02610.x     Document Type: Article

References (12)

1. Gringeri A, Mannucci PM. National survey of human immunodeficiency virus infection in Italian hemophiliacs: 1983-1987. The Medical-Scientific Committee of the Fondazione dell'Emofilia. Ric Clin Lab 1988; 18: 275-80.
2. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003; 5: 36-43.
3. Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection. Haemophilia 2009; 15: 552-8.
4. European Medicines Agency (EMA). Summary of the European Public Assessment Report (EPAR) for Isentress, Merck Sharp & Dohme Ltd., Hertfordshire, UK. Last update 12/05/2010. Available at Accessed July 4, 2011.
5. Grinsztejn B, Nguyen B-Y, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369: 1261-9.
6. Powderly WG. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother 2010; 65: 2485-8.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Bethesda, Maryland, USA: Department of Health and Human Services. January 10, 2011; 1-166. Available at Accessed March 8, 2011.
8. Stanworth SJ, Bolton MJ, Hay CRM, Shiach CR. Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Haemophilia 1998; 4: 109-14.
9. FDA - Food and Drug Administration. Traditional Approval of Isentress (Raltegravir). Page last updated: 07/01/2009. Available at Accessed March 7, 2011.
10. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. Clin Physiol Funct Imaging 2010; 30: 187-91.
11. Croxtall JD, Keam SJ. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009; 69: 1059-75.
12. Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther 2008; 30: 1747-65.